Liver Abnormalities in Systemic Lupus Erythematosus: A Prospective Observational Study

Area of Science:

• Hepatology
• Rheumatology
• Internal Medicine

Background:

• Systemic lupus erythematosus (SLE) can manifest with liver abnormalities.
• Lupus hepatitis is a recognized, though less common, manifestation of SLE.
• Understanding the prevalence and characteristics of liver involvement in SLE is important for patient management.

Purpose of the Study:

• To investigate the spectrum and prevalence of liver abnormalities in SLE patients.
• To specifically determine the incidence and clinical features of lupus hepatitis.
• To differentiate lupus hepatitis from other causes of liver dysfunction in SLE.

Main Methods:

• Prospective observational study design.
• Inclusion of both newly diagnosed and follow-up SLE patients.
• Systematic recording and evaluation of clinical data, liver function tests (LFTs), and abdominal ultrasonography findings.

Main Results:

• 20.7% of 135 SLE patients exhibited liver abnormalities.
• Transaminitis (elevated AST/ALT) occurred in 10 patients; 7 were classified as lupus hepatitis (5.2%).
• Lupus hepatitis was more prevalent in newly diagnosed SLE patients (85.7%) versus follow-up patients (23.6%) and resolved in all cases.

Conclusions:

• Transaminitis due to lupus hepatitis occurs in newly diagnosed SLE and is not linked to disease activity.
• Drug-induced liver injury must be excluded before diagnosing lupus hepatitis.
• Persistent LFT abnormalities warrant further investigation for overlapping liver conditions like primary biliary cirrhosis or autoimmune hepatitis.